EPO and anemia (phenotype): Recombinant human erythropoietin (rHuEPO) was an erythropoiesis stimulating agent (ESA) introduced into clinical practice to treat anemia related to CKD in the 1990s and successfully improved clinical outcomes and quality of life of patients with CKD1.